United States Federal Circuit
AstraZeneca Pharm. LP v. Teva Pharm. USA, Inc., 08-1480
In a patent case involving claims for the antipsychotic drug quetiapine, district court's grant of limited motion for summary judgment of no inequitable conduct in favor of plaintiffs-AstraZeneca is affirmed as defendants had not presented evidence sufficient for a reasonable jury to find that in the prosecution of the patent application, plaintiff made a misrepresentation of material fact or an omission of material fact, with intent to deceive or mislead the patent examiner into granting the patent.
Appellate Information
- Decided 09/25/2009
- Published 09/25/2009
Judges
Court
- United States Federal Circuit